ALSE Alseres Pharmaceuticals Inc (CE)

CUSIP No.  021152103



--------------------------------------------------------------------------------
   1.  NAME OF REPORTING PERSON(S)
       S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON(S)

        INGALLS & SNYDER LLC

        13-5156620

--------------------------------------------------------------------------------
   2.  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

         (a)  [  ]
         (b)  [  ]


--------------------------------------------------------------------------------
   3.  SEC USE ONLY




--------------------------------------------------------------------------------
   4.  CITIZENSHIP OR PLACE OF ORGANIZATION


     NEW YORK STATE

--------------------------------------------------------------------------------
   NUMBER OF      5.   SOLE VOTING POWER
     SHARES             0
BENEFICIALLY    --------------------------------------------------------------
    OWNED BY      6.   SHARED VOTING POWER
      EACH              0
   REPORTING      --------------------------------------------------------------
     PERSON       7.   SOLE DISPOSITIVE POWER
      WITH              0
--------------------------------------------------------------
                  8.   SHARED DISPOSITIVE POWER

                        100,000
--------------------------------------------------------------------------------
   9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                        100,000
--------------------------------------------------------------------------------
  10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*



--------------------------------------------------------------------------------
  11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

            0.0%
--------------------------------------------------------------------------------
  12.  TYPE OF REPORTING PERSON*

                  BD, IA
--------------------------------------------------------------------------------


Item 1.     (a)   Name of Issuer:

                        ALSERES PHARMACEUTICALS, INC.
                  --------------------------------------------------------------
            (b)   Address of Issuer's Principal Executive Offices:

                        239 SOUTH STREET
                        HOPKINTON, MA 01748
                  --------------------------------------------------------------
Item 2.     (a)   Name of Person Filing:


                   INGALLS & SNYDER LLC
                  --------------------------------------------------------------
            (b)   Address of Principal Business Office, or if None, Residence:


                  61 BROADWAY, NEW YORK, NY 10006


                  --------------------------------------------------------------
            (c)   Citizenship:
                             NEW YORK STATE
                  --------------------------------------------------------------
            (d)   Title of Class of Securities:
                                COMMON STOCK
                  --------------------------------------------------------------
            (e)   CUSIP Number:
                                021152103
                  --------------------------------------------------------------


Item 3.     If this statement  is filed  pursuant to Rules 240.13d-(1), or
            13d-2(b) or (c), check whether the person filing is a:

            (a)   [X]   Broker or Dealer  registered under Section  15 of  the
                        Act, (15 U.S.C 78o)

            (b)   [ ]   Bank as defined in Section 3(a)(6) of the
                        Act, (15 U.S.C 78c)

            (c)   [ ]   Insurance Company  as defined  in Section  3(a)(19) of
                        the Act, (15 U.S.C 78c)

            (d)   [ ]   Investment Company registered under  Section 8 of  the
                        Investment Company Act of 1940 (15 U.S.C 80a-8)

            (e)   [X]   Investment Adviser in accordance with Section
                        240.13d-1(b)(1)(ii)(E)

            (f)   [ ]   Employee Benefit Plan or endowment fund in accordance
                        to Section 240.13d-1(b)(ii)(F)

            (g)   [ ]   A parent holding company or control person in
                        accordance with Section 240.13d-1(b)(1)(ii)(G)


            (h)   [ ]   A savings associations as defined in Section 3(b) of the
                        Federal Deposit Insurance Act (12 U.S.C 1813)

            (i)   [ ]   A church plan that is excluded from the definition of an
                        investment company under section 3(c)(14) of
                        the Investment Company Act of 1940 (15 U.S.C 80a-3)

            (j)   [ ]   Group, in accordance with Section 240.13d-1(b)(1)(ii)(J)



Item 4.     Ownership.

            (a) Amount beneficially owned: 100,000----------,

            (b) Percent of class: 0.0%----------------------,

            (c) Number of shares as to which such person has:

                  (i) Sole power to vote or to direct the vote
                        0--,

                  (ii) Shared power to vote or to direct the vote
                        0------,

                  (iii) Sole power to dispose or to direct the disposition of
                        0-----,


                  (iv) Shared power to dispose or to direct the disposition of
                        100,000------


Item 5.     Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following [ ].
                INAPPLICABLE

Item 6.     Ownership of More Than Five Percent on Behalf of Another Person.


Securities reported under Shared Dispositve Power include securities
owned by clients of Ingalls & Snyder LLC ("Ingalls"), a registered
broker dealer and a registered investment advisor, in accounts managed under
investment advisory contracts.


All shares reported assume the exercise of all warrants owned by Gipson.




Item 7.     Identification and Classification of the Subsidiary which Acquired
            the Security Being Reported on By the Parent Holding Company.

                INAPPLICABLE

Item 8.     Identification and Classification of Members of the Group.

                INAPPLICABLE

Item 9.     Notice of Dissolution of Group.

                INAPPLICABLE


Item 10.    Certification.



            By  signing  below I certify  that,  to the  best  of  my knowledge
and belief, the securities referred to above were acquired and are held in the
ordinary  course of business  and were not  acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities  and were not acquired and are not held in connection
with or as a participant in any  transaction  having that purpose or effect.

                                  Signature.


            After reasonable inquiry and to the best of my knowledge and
            belief, I certify  that the  information  set  forth in this
            statement is true, complete and correct.

Date: 01/25/13

BY: Ingalls & Snyder, LLC

/s/ THOMAS O. BOUCHER, JR
----------------------------------
                      (Signature)*

THOMAS O. BOUCHER, JR
----------------------------------
Managing Director

(Name/Title)